Taft Pharmaceutical & Life Sciences Chair Stephen Auten is quoted in the Feb. 8 Law360 article “USPTO’s Take on Reused PTAB Positions May Upend Strategy.” The article focuses on the USPTO’s amicus brief in support of the position that a successful IPR defense should be barred at trial.

Auten states “The impact would be particularly strong for generic-drug makers, who must prevail in a district court patent case in order to get approval for their abbreviated new drug applications.”